Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–91 of 91 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High-Dose Conformal Radiation Therapy Clear all

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiotherapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, goserelin, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Prostate Cancer
Interventions: carboplatin, estramustine, paclitaxel, radiation therapy, leuprolide or goserelin acetate; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 23
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Worcester, Massachusetts + 12 more

Conditions: Medulloblastoma
Interventions: Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation; Radiation · Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 39 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 14
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: busulfan, etoposide, intensity-modulated radiation therapy, allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, tomotherapy; Drug · Radiation · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 6 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2022
U.S. locations: 72
States / cities: Long Beach, California • Sacramento, California • San Francisco, California + 55 more

Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection; Biological · Radiation · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT; Radiation · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: brachytherapy, hypofractionated radiation therapy, image-guided radiation therapy, intensity-modulated radiation therapy; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more

Conditions: High Grade Sarcoma
Interventions: Intensity Modulated Radiation Therapy (IMRT), MRI; Radiation · Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: Radiation, Androgen Suppression Therapy; Radiation · Drug
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 4
States / cities: Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more

Conditions: Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Interventions: Intensity-modulated radiation therapy, Carboplatin, Paclitaxel; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor
Interventions: 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Thiotepa, Vincristine Sulfate; Radiation · Procedure · Drug + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 87
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 72 more

Conditions: Xerostomia
Interventions: D-Limonene Gelcaps, Intensity modulated radiotherapy (IMRT), Cisplatin, Xerostomia questionnaire; Drug · Radiation · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cervical Cancer
Interventions: carboplatin, cisplatin, paclitaxel, intensity-modulated radiation therapy, standard external beam radiation therapy, Optional brachytherapy boost; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 98 more

Conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration; Drug · Procedure · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 338
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more

Conditions: Prostate Cancer
Interventions: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT; Drug
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Cisplatin, Cetuximab, IMRT; Drug · Radiation
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more

Search by objective public record fields.

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer